Skip to main content
Beta Drugs Limited logo

Beta Drugs Limited — Investor Relations & Filings

Ticker · BETA ISIN · INE351Y01019 LEI · 984500A89888DB9E6T57 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 431 across all filing types
Latest filing 2025-05-15 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BETA

About Beta Drugs Limited

https://www.betadrugslimited.com

Beta Drugs Limited specializes in the development, manufacture, and marketing of oncology formulations. The company provides a comprehensive portfolio of anti-cancer drugs across various therapeutic segments, including cytotoxic injectables, lyophilized products, tablets, and capsules. Its manufacturing capabilities encompass a wide range of oncology treatments such as chemotherapy agents and supportive care medications. The organization operates advanced production facilities designed to meet international quality standards, focusing on high-potency active pharmaceutical ingredients and finished dosage forms. The company serves diverse markets through its own branded products and contract manufacturing services, aiming to provide affordable and high-quality cancer care solutions. Its core competency lies in its specialized focus on the oncology niche and its integrated approach to pharmaceutical production.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2025-05-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 70% confidence The document is an invitation and announcement for an upcoming earnings conference call scheduled for May 16, 2025, to discuss the operational and financial performance of Beta Drugs Ltd. It includes details about the call timing, speakers, dial-in numbers, and registration information. There is no actual financial data or results presented in this document, nor is it a transcript of the call. The document is essentially a notice about the earnings call event, not the earnings release or the transcript itself. Therefore, the appropriate classification is 'Call Transcript' (CT) because it relates to the earnings call, but since it is only an invitation and not the transcript, the best fit is the category for call-related documents. However, given the definitions, 'Call Transcript' is for full text transcripts, and this is an invitation. The document is an announcement of the call, which is closest to a Regulatory Filing (RNS) as a general regulatory announcement about the call. But since the document is specifically about the earnings conference call, the best classification is 'Call Transcript' (CT) with moderate confidence, acknowledging it is not the transcript but related to the call event.
2025-05-12 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-05-09 English
Updates
Regulatory Filings Classification · 95% confidence The document is a company announcement about regulatory approval (COFEPRIS) for manufacturing plants, highlighting compliance and market expansion. It does not contain financial statements, detailed financial data, or report content. The document length is short (2100 characters) and reads as a news or regulatory update rather than a formal report. There is no indication of an annual report, audit report, earnings release, or other formal filings. It is an announcement of regulatory approval and business update, fitting best under Regulatory Filings (RNS) as a general regulatory announcement.
2025-05-05 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate issued under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms the processing of securities dematerialisation requests for the quarter ended 31st March 2025. The document is a compliance certificate from a registrar and transfer agent to the company, confirming regulatory compliance related to securities dematerialisation. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS), which covers compliance documents and certifications that do not fit other categories.
2025-04-08 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2025-04-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.